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z Evidence summary
Sexual dysfunction includes desire, 
arousal, orgasmic, and sex pain disorders. 
In the US, 43% of women and 31% of 
men experience sexual dysfunction. Since 
sexual dysfunction increases with age, 
the prevalence will likely increase with 
the aging American population. 2
Testosterone helps men, 
but long-term risks are unclear
Several cross-sectional and longitudinal 
studies3,4 demonstrate that serum to-
tal and free testosterone concentrations 
in men decline with age. Although the 
decline is gradual, by the eighth decade 
30% of men have total testosterone val-
ues in the hypogonadal range and 50% 
have low free testosterone values.4 
In randomized, placebo-controlled 
trials5,6 of older men with low testoster-
one concentrations, testosterone admin-
istration was associated with a sustained 
increase in testosterone levels over 1 to 
3 years. Regardless of the route of ad-
ministration (gel, transdermal patch, or 
intramuscular injection), testosterone re-
placement results in improved libido and 
sexual function for men with low testos-
terone levels.6–8 The caveat, though, is 
Offer testosterone replacement—and 
candid talk about risks and alternatives
sexual	dysfunction	is	a	relatively	frequent	
complaint	from	elderly	patients,	and	its	
multifactorial	nature	must	be	investigated.	
if	you	discover	low	or	hypogonadal	
testosterone	levels	in	a	male	patient,	
offer	replacement	therapy.	Be	sure,	too,	
to	discuss	the	risks	and	the	alternatives	
(including	psychological	aspects	of	care	
and	partner	communication).	if	your	
patient	is	a	postmenopausal	woman	who	
is	interested	in	combination	estrogen	and	
testosterone	therapy,	you	should	counsel	
her	on	the	estimated	17%	increased	risk		
of	breast	cancer	per	year	of	use.1
Robert K. Persons, DO, FaaFP
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Clinical commentary
Evidence-based answer
Yes,	testosterone	therapy	is	effective	in	
improving	libido	for	elderly	hypogonadal	
males	(strength	of	recommendation	[sor]:	
B,	based	on	small	randomized	controlled	
trials	[rCTs]).	Testosterone	combined	
with	estrogen	can	also	improve	libido	
for	postmenopausal	women,	but	it’s	
not	approved	by	the	us	Food	and	Drug	
administration	(FDa)	for	this	purpose	(sor:	
B,	based	on	small	rCTs).	
Krupa Shah, MD  
and Cathy Montoya, MlS
Baylor College of Medicine, 
Houston, Tex
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that  testosterone trials of older men are 
characterized by very small sample sizes 
(n=10–50), disparate outcome measures, 
and the inclusion of men who were not 
uniformly testosterone-deficient and were 
asymptomatic.
In addition, these studies did not 
have sufficient power to detect either 
meaningful gains in patient-important 
outcomes or changes in prostate or car-
diovascular event rates.5,6,8,9 Thus, the 
long-term benefit/risk ratio of testoster-
one replacement therapy for aging hypo-
gonadal men is unknown.
Less evidence for women
Up to 50% of postmenopausal women 
experience sexual dysfunction,10 and a 
low testosterone level is correlated with a 
decreased coital frequency.11 Some studies 
suggest that testosterone at supraphysio-
logical doses—by injections, implants, or 
pill (in combination with estrogen)—im-
proves libido and sexual function.12–14 
The downside is that these studies are 
very small and have several methodologi-
cal shortcomings. The pharmacokinetics 
of testosterone formulations for women 
are unclear, and the assays for the mea-
surement of total and free testosterone 
concentrations in women lack accuracy 
and sensitivity. Long-term safety stud-
ies on breast cancer and cardiovascular 
events are lacking. 
Testosterone’s major adverse effects 
include virilization (oily skin, acne, hir-
sutism, alopecia, deep voice), liver toxic-
ity, polycythemia, breast carcinoma, and 
unfavorable changes in cardiovascular 
risk markers such as reduction in high-
density lipoprotein cholesterol or insulin 
sensitivity.5–8,12–15
Recommendations from others
American Association of Clinical Endo-
crinologists guidelines for menopause16 
recommends against the general use of 
testosterone therapy at menopause, ex-
cept for women with continuing symp-
toms during adequate estrogen therapy.
The Endocrine Society17 recommends 
that clinicians consider offering testoster-
one therapy on an individualized basis to 
older men with low testosterone levels 
and significant symptoms of testosterone 
androgen deficiency. Before administra-
tion, it’s important to discuss the uncer-
tainties, risks, and benefits of testosterone 
therapy in older men. 
The Endocrine Society also recom-
mends against starting testosterone ther-
apy for patients with breast or prostate 
cancer, a palpable prostate nodule or in-
duration or prostate-specific antigen >3 
ng/mL without further urological evalu-
ation, erythrocytosis (hematocrit >50%), 
hyperviscosity, untreated obstructive 
sleep apnea, severe lower urinary tract 
symptoms with an International Prostate 
Symptom Score (IPSS) >19, or class III or 
IV heart failure. When testosterone ther-
apy is instituted, the goal should be to 
achieve testosterone levels in the midnor-
mal range. This guideline recommends 
evaluating the patient 3 months after 
treatment initiation and then annually to 
assess whether he or she has responded 
to treatment and whether the patient is 
suffering any adverse effects.17
The Institute of Medicine examined 
the effectiveness and safety of testoster-
one therapy for older men. The report18 
states that its use is appropriate only for 
those conditions approved by the FDA 
(primary and secondary hypogonadism 
among men), and that it is inappropriate 
to use testosterone replacement therapy 
to prevent possible future disease for 
otherwise healthy older men. The com-
mittee found no compelling evidence of 
major adverse effects resulting from tes-
tosterone therapy.18  n
references
	 1.	 	Tamimi	 rM,	 Hankinson	 se,	 Chen	 WY,	 rosner	 B,	
Colditz	 Ga.	 Combined	 estrogen	 and	 testosterone	
use	 and	 risk	 of	 breast	 cancer	 in	 postmenopausal	
women. Arch Intern Med 2006;	166:1483–1489.	
	 2.	 	laumann	 eo,	 paik	 a,	 rosen	 rD.	 sexual	 dysfunc-
tion	in	the	united	states:	prevalence	and	predictors.	
JAMA 1999;	281:537–544.
	 3.	 	Feldman	 Ha,	 longcope	 C,	 Derby	 Ca,	 et	 al.	 age	
trends	 in	 the	 level	of	serum	 testosterone	and	other	
hormones	 in	middle-aged	men:	 longitudinal	 results	
The goal should be 
a testosterone level 
in the midnormal 
range
from	the	Massachusetts	Male	aging	study.	J Clin En-
docrinol Metab 2002;	87:589–598.	
	 4.	 	Harman	sM,	Metter	eJ,	Tobin	JD,	pearson	J,	Black-
man	Mr.	longitudinal	effects	of	aging	on	serum	total	
and	free	testosterone	levels	in	healthy	men.	Baltimore	
longitudinal	study	of	aging.	J Clin Endocrinol Metab 
2001;	86:724–731.
	 5.	 	amory	 JK,	Watts	NB,	easley	Ka,	 et	 al.	 exogenous	
testosterone	 or	 testosterone	 with	 finasteride	 in-
creases	bone	mineral	density	in	older	men	with	low	
serum	 testosterone.	J Clin Endocrinol Metab	 2004;	
89:503–510.
	 6.	 	snyder	pJ,	peachey	H,	Hannoush	p,	et	al.	effect	of	
testosterone	 treatment	 on	 body	 composition	 and	
muscle	strength	in	men	over	65	years	of	age.	J Clin 
Endocrinol Metab 1999;	84:2647–2653.
	 7.	 	Cavallini	 G,	 Caracciolo	 s,	 vitali	 G,	Modenini	 F,	 Bi-
agiotti	G.	Carnitine	 versus	 androgen	 administration	
in	 the	 treatment	 of	 sexual	 dysfunction,	 depressed	
mood,	and	fatigue	associated	with	male	aging.	Urol-
ogy	2004;	63:641–646.
	 8.	 	page	sT,	amory	JK,	Bowman	FD,	et	al.	exogenous	
testosterone	 (T)	 alone	 or	 with	 finasteride	 increases	
physical	performance,	grip	strength,	and	 lean	body	
mass	in	older	men	with	low	serum	T.	J Clin Endocrinol 
Metab	2005;	90:1502–1510.
	 9.	 	sih	r,	Morley	Je,	Kaiser	Fe,	perry	3rd	HM,	patrick	p,	
ross	C.	Testosterone	replacement	in	older	hypogo-
nadal	men:	a	12-month	randomized	controlled	trial. J 
Clin Endocrinol Metab	1997;	82:1661–1667.
	10.	 	Bachmann	Ga,	leiblum	sr,	sandler	B,	et.	al.	Cor-
relates	of	sexual	desire	in	post-menopausal	women.	
Maturitas 1985;	7:211–216.
	11.	 	McCoy	Nl,	Davidson	JM.	a	longitudinal	study	of	the	
effects	of	menopause	on	sexuality.	Maturitas	 1985;	
7:203–210.
	12.	 	Davis	sr,	McCloud	p,	strauss	BJ,	Burger	H.	Testos-
terone	 enhances	 estradiol’s	 effects	 on	 postmeno-
pausal	 bone	 density	 and	 sexuality.	Maturitas 1995;	
21:227–236.
	13.	 	sarrel	p,	Dobay	B,	Wiita	B.	estrogen	and	estrogen-
androgen	 replacement	 in	 postmenopausal	 women	
dissatisfied	 with	 estrogen-only	 therapy.	 sexual	 be-
havior	and	neuroendocrine	responses.	J Reprod Med	
1998;	43:847–856.
	14.	 	sherwin	BB,	Gelfand	MM,	Brender	W.	androgen	en-
hances	 sexual	 motivation	 in	 females:	 a	 prospective,	
crossover	study	of	sex	steroid	administration	in	the	sur-
gical	menopause.	Psychosom Med	1985;	47:339–351.
	15.	 	Gelfand	 MM,	Wiita	 B.	 androgen	 and	 estrogen-an-
drogen	 hormone	 replacement	 therapy:	 a	 review	 of	
the	 safety	 literature,	 1941	 to	1996.	Clin Ther	 1997;	
19:383–404.
	16.	 	aaCe	Menopause	Guidelines	revision	 Task	 Force.	
american	 association	 of	 Clinical	 endocrinologists	
medical	guidelines	for	clinical	practice	for	the	diagno-
sis	and	treatment	of	menopause.	Endocr Pract	2006;	
12:315–337.	
	17.	 	Bhasin	s,	Cunningham	Gr,	Hayes	FJ,	et	al.	Testos-
terone	therapy	in	adult	men	with	androgen	deficiency	
syndromes:	 an	 endocrine	 society	 clinical	 practice	
guideline.	 J Clin Endocrinol Metab	 2006;	 91:1995–
2010.
	18.	 	liverman	CT,	Blazer	DG	(eds).	Testosterone and Ag-
ing: Clinical Research Directions. Washington,	 DC:	
National	academies	press,	2004.		
AvAilAble At www.jfponline.com
intrauterine copper contraceptive 
Update and Opportunities
This supplement is supported by a grant from Duramed Pharmaceuticals Inc. 
     Experts dispel myths about intrauterine device usage, 
describe changes to the prescribing information for  
the ParaGard® T380A intrauterine copper contraceptive,  
and explain the potential effect these changes have  
on clinical practice.
Anita L. Nelson, MD   ●   David Grimes, MD   ●   Raquel Arias, MD   
Lee Shulman, MD   ●   Anne Moore, MSN, ANP
Testosterone injections for increasing libido
